Adenosine and diltiazem. A new therapeutic concept in the treatment of intestinal ischemia.
To determine the therapeutic effect of two vasodilators, adenosine and diltiazem, in mesenteric ischemia, 13 dogs were treated with an intra-arterial perfusion of the drugs after digitalis intoxication. Blood flow was restored to the control value after a dose of 2 micrograms/kg/minute adenosine or 5 micrograms/kg/minute diltiazem. The advantage of adenosine is that its effect begins and ends very rapidly, but because doses of more than 2 micrograms/kg/minute may cause a drop in blood pressure, strict pressure control is mandatory when the drug is applied clinically. Its limited use is appropriate, for example, when operative measures cannot be excluded. Diltiazem can be used for long-term therapy with a reduced risk of a drop in blood pressure.
D000241:Adenosine / Q000627:therapeutic use*; D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use*; D004110:Diltiazem / Q000627:therapeutic use*; D004285:Dogs; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D007422:Intestines / Q000098:blood supply*; D007511:Ischemia / Q000188:drug therapy*; D008297:Male; D012263:Ribonucleosides / Q000627:therapeutic use*; D012265:Ribonucleotides / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D001552:Benzazepines; D004338:Drug Combinations; D012263:Ribonucleosides; D012265:Ribonucleotides; D014665:Vasodilator Agents; C045199:Laevodosin; D004110:Diltiazem; D000241:Adenosine